



## Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023

February 9, 2023 at 8:00 AM EST

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter 2022 financial results on Thursday, February 23, 2023. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and certain business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at <http://investors.vcel.com/events-presentations>. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.

To participate by telephone, please [register here](#) to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until February 23, 2024.

### About Vericel Corporation

Vericel is a leader in advanced therapies for sports medicine and severe burn care. The Company manufactures and markets two cell therapy products and one specialty biologic product in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit [www.vcel.com](http://www.vcel.com).

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2023 Vericel Corporation. All rights reserved.

### Investor Contact:

Eric Burns  
ir@vcel.com  
+1 (734) 418-4411

### Media Contact:

Julie Downs  
media@vcel.com